Amicus’s path to unseat Sanofi in rare disease gets steeper after Phase 3 miss

Amicus Therapeutics CEO John Crowley said the totality of data support the Pompe disease therapy’s submission to the FDA. That rolling application is on track for completion in the second quarter.